These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17404699)

  • 21. Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine.
    Djalalov S; Yong J; Beca J; Black S; Saposnik G; Musa Z; Siminovitch K; Moretti M; Hoch JS
    Mol Diagn Ther; 2012 Dec; 16(6):389-99. PubMed ID: 23188525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of donepezil therapy on health costs in a Medicare managed care plan.
    Hill JW; Futterman R; Mastey V; Fillit H
    Manag Care Interface; 2002 Mar; 15(3):63-70. PubMed ID: 11925682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
    Gustavsson A; Jönsson L; Parmler J; Andreasen N; Wattmo C; Wallin ÅK; Minthon L
    Eur J Health Econ; 2012 Oct; 13(5):561-8. PubMed ID: 21822729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Delaying Alzheimer dementia. Patient and family relieved--costs lowered].
    MMW Fortschr Med; 2000 Aug; 142(33-34):56-7. PubMed ID: 10998909
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cost-effectiveness of galantamine in a german context].
    Happich M; Schweikert B; Mühlbacher A
    Psychiatr Prax; 2005 Apr; 32(3):142-50. PubMed ID: 15818530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model.
    Kasuya M; Meguro K
    Arch Gerontol Geriatr; 2010; 50(3):295-9. PubMed ID: 19481822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
    Courtney C; Farrell D; Gray R; Hills R; Lynch L; Sellwood E; Edwards S; Hardyman W; Raftery J; Crome P; Lendon C; Shaw H; Bentham P;
    Lancet; 2004 Jun; 363(9427):2105-15. PubMed ID: 15220031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
    Truter I
    Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.
    Wimo A; Winblad B; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Mastey V; Haglund A; Zhang R; Miceli R; Chin W; Subbiah P;
    Dement Geriatr Cogn Disord; 2003; 15(1):44-54. PubMed ID: 12457078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
    van Hout HP; Bosmans JE; Stalman WA
    Neurology; 2005 Apr; 64(7):1320; author reply 1320. PubMed ID: 15824386
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
    Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.
    Whitehouse PJ; Winblad B; Shostak D; Bhattacharjya A; Brod M; Brodaty H; Dor A; Feldman H; Forette F; Gauthier S; Hay J; Henke C; Hill S; Mastey V; Neumann P; O'Brien B; Pugner K; Sano M; Sawada T; Stone R; Wimo A
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):266-80. PubMed ID: 9876955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relief for caregivers. Anti-dementia drug saves costs].
    MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697297
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
    Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
    Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equity in the new NHS: hard lessons from implementing a local healthcare policy on donepezil.
    Doyle Y
    BMJ; 2001 Jul; 323(7306):222-4. PubMed ID: 11473920
    [No Abstract]   [Full Text] [Related]  

  • 37. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 38. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea.
    Suh GH
    Value Health; 2009; 12 Suppl 3():S49-54. PubMed ID: 20586982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany.
    Froelich L; Gertz HJ; Heun R; Heuser I; Jendroska K; Kornhuber J; Kurz A; Mueller-Thomsen T; Ries F; Waechtler C; Metz M; Goebel C
    Dement Geriatr Cogn Disord; 2004; 18(1):37-43. PubMed ID: 15084792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.